Exicure, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 2 selling0 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
- Funds5 adding, 7 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 38% in the quarter to 2022-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Exicure, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 109% and a beta of -0.0 against the S&P 500.
- Insiders selling. 2 insiders sold $12M of stock over the past 365 days and none bought (0% under pre-set trading plans).
- Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.
Latest results
- Earnings per share
- -$8.30 against an average estimate of -$6.00: missed by 38.3%
- Share reaction
- +3.1% in the first session after the results on March 25, 2026, against -1.2% for the S&P 500
Price chart
- 1 day+1.0%
- 1 week-6.4%
- 1 month-11.3%
- This year-81.2%
- 1 year-76.8%
- 5 years-99.4%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- March 25, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for XCUR from the sources we follow. See filings →
No model value for Exicure, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Exicure, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.95 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Exicure, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Exicure, Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2022 | −$6.00 | −$8.30 | −38.3% |
| Mar 2022 | −$10.50 | −$10.50 | 0.0% |
| Dec 2021 | −$21.00 | −$22.50 | −7.1% |
| Sept 2021 | −$22.50 | −$40.50 | −80.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 1.3% of tradable shares
- Days to cover
- 1.42 at average volume
- Short interest, 1 month
- −39% to October 15, 2026
- Held by institutions
- 2% of shares
- Held by insiders
- 41.5% of shares
- Employees
- 1 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| XCUR | −89% | −81% | −50% | +371% | −60% | −81% |
| Industry peers (median) | −35% | −56% | −17% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| XCUR | 33% | 25% | 33% | 33% | 33% | 18% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| XCUR | −93% | −92% | −77% | −64% | −77% | −86% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since May 22, 2018: 100% from September 18, 2018 to October 29, 2026. Getting back needed a 104178% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.94 – $7.29
- From 52-week high
- −86.0%
- vs 50-day average
- −14.0%
- vs 200-day average
- −62.1%
- Volatility (1 year)
- 109%
- Beta vs S&P 500
- -0.03
Share price after results
- Next day
- 4 up, 8 down typical move ±6.0%
- After a week
- 2 up, 10 down typical move ±33.9%
- After a month
- 2 up, 10 down typical move ±73.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| March 25, 2026 | +3.1% | −1.2% | −6.5% | −22.4% |
| November 7, 2025 | −8.9% | +1.7% | −12.7% | +71.5% |
| August 8, 2025 | +3.0% | +0.6% | −9.6% | −43.6% |
| March 18, 2025 | −0.7% | 0.0% | +2.2% | −11.1% |
| November 14, 2024 | +6.2% | −1.9% | +297.8% | +563.7% |
| June 17, 2024 | 0.0% | +1.1% | −4.5% | −7.9% |
| June 6, 2024 | −20.8% | −0.1% | −33.0% | −40.0% |
| May 16, 2024 | −0.8% | −0.1% | −10.4% | −37.0% |
| August 11, 2023 | −3.4% | +0.5% | −3.1% | −3.4% |
| July 14, 2023 | +3.2% | +0.3% | −14.3% | −34.1% |
| March 27, 2023 | −15.6% | 0.0% | −8.3% | −3.4% |
| November 14, 2022 | −6.5% | 0.0% | −4.1% | −39.8% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $284,325
- Institutions reporting
- 16
- Shares held vs prior quarter
- ▼ 15.2%
- Positions opened / closed
- 2 / 3
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Vanguard Capital Management LLC | $89,671 | 43K | 31.5% | ▲ 30.7% |
| Geode Capital Management, LLC | $65,009 | 31K | 22.9% | ▼ 15.3% |
| Jane Street Group, LLC | $61,433 | 30K | 21.6% | New |
| Citadel Advisors LLC | $31,032 | 15K | 10.9% | New |
| Vanguard Fiduciary Trust Co | $27,375 | 13K | 9.6% | 0.0% |
| Tower Research Capital LLC (TRC) | $8,474 | 4K | 3.0% | ▲ 733.1% |
| UBS Group AG | $711 | 0K | 0.3% | ▼ 60.5% |
| Morgan Stanley | $297 | 0K | 0.1% | ▼ 9.5% |
| Sbi Securities Co., Ltd. | $89 | 0K | 0.0% | 0.0% |
| Blackrock, Inc. | $73 | 0K | 0.0% | ▼ 99.6% |
| Osaic Holdings, Inc. | $60 | 0K | 0.0% | 0.0% |
| Prestige Wealth Management Group LLC | $42 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Exicure, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Exicure Hitron Inc. 10% owner | January 21, 2026 | Sell | 258,367 | $4.50 | $1.2M |
| Exicure Hitron Inc. 10% owner | January 16, 2026 | Sell | 734,747 | $4.50 | $3.3M |
| Exicure Hitron Inc. 10% owner | January 7, 2026 | Sell | 741,272 | $4.50 | $3.3M |
| Sangsangin Investment & Securities Co., Ltd. 10% owner | December 8, 2025 | Sell | 433,332 | $8.71 | $3.8M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- March 25, 2026
- November 7, 2025
- August 8, 2025
- March 18, 2025
- November 14, 2024
- June 17, 2024
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Exicure, Inc. in brief
- What does Exicure, Inc. do?
- Exicure, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Exicure, Inc.'s stock ticker?
- Exicure, Inc. trades under the ticker XCUR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Exicure, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Geode Capital Management, LLC and Jane Street Group, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Exicure, Inc. stock?
- Over the last 12 months, Exicure, Inc.'s directors and officers reported 0 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
Follow research on Exicure, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.